1. Home
  2. NTZ vs LITS Comparison

NTZ vs LITS Comparison

Compare NTZ & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Natuzzi S.p.A.

NTZ

Natuzzi S.p.A.

HOLD

Current Price

$2.22

Market Cap

28.0M

ML Signal

HOLD

LITS

Lite Strategy Inc.

HOLD

Current Price

$0.74

Market Cap

25.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTZ
LITS
Founded
1959
2000
Country
Italy
United States
Employees
N/A
4
Industry
Home Furnishings
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.0M
25.7M
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
NTZ
LITS
Price
$2.22
$0.74
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
3.5K
532.6K
Earning Date
04-13-2023
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.15
$0.69
52 Week High
$3.95
$3.03

Technical Indicators

Market Signals
Indicator
NTZ
LITS
Relative Strength Index (RSI) 34.11 27.30
Support Level $2.16 N/A
Resistance Level $3.16 $1.23
Average True Range (ATR) 0.12 0.08
MACD -0.01 -0.02
Stochastic Oscillator 10.00 15.24

Price Performance

Historical Comparison
NTZ
LITS

About NTZ Natuzzi S.p.A.

Natuzzi SpA is an Italian firm that designs, manufactures, and sells contemporary and traditional leather and fabric-upholstered furniture. Its product portfolio includes sofas, loveseats, armchairs, sectional furniture, motion furniture, sofa beds, living room furnishings, and accessories. The company markets its products under several brands such as Natuzzi Italia, Private Label, and Natuzzi Editions. The Group operates in two operating segments, the Natuzzi brand and Private label. The Natuzzi brand segment includes net sales from the Natuzzi Italia, Natuzzi Editions, and Divani&Divani by Natuzzi product lines. Geographically, it derives a majority of its revenue from the United States of America and also has an international presence in Italy, Spain, the UK, China, and Other countries.

About LITS Lite Strategy Inc.

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Share on Social Networks: